Sandoz Recalls Ranitidine Drugs, Citing NDMA Carcinogen Contamination




WASHINGTON, D.C. — Sandoz Inc. has announced that it is voluntarily recalling all of its ranitidine drugs in the United States due to contamination by a probable human carcinogen known as N-Nitrosodimethylamine (NDMA), according to a MedWatch Safety Alert.

The Sept. 24 alert adds that Sandoz has not received any reports of adverse events related to use of the drugs. The recall implicates the company’s 150mg and 300mg ranitidine hydrochloride capsules.

“Pharmacies should immediately stop dispensing Sandoz's Ranitidine Hydrochloride Capsules and return remaining stock to Sandoz,” the alert says. “Consumers should continue taking their medication and speak to their physician …






UPCOMING CONFERENCES




HarrisMartin’s Webinar Series: Acetaminophen ASD/ADHD Product Liability Litigation

October 21, 2022

MORE DETAILS



HarrisMartin's Webinar Series: The Hottest Upcoming Device Projects - Strattice Hernia Mesh & Exactech Hip Implants

November 09, 2022

MORE DETAILS